PROSECCO Trial: Cemiplimab Combination for Melanoma

The PROSECCO trial has been registered on ClinicalTrials.gov under identifier NCT07511036. This is a clinical study investigating cemiplimab (Libtayo), Regeneron's PD-1 checkpoint inhibitor, in combination therapy for melanoma. The trial status is listed as 'not recruiting,' indicating the study has been registered but participant enrollment has not yet begun or is currently paused.

Pharmaceutical companies and clinical investigators involved in oncology trials should ensure their trial registrations are current and accurately reflect study status. Compliance with FDA requirements for clinical trial registration under FDAAA 801 and International Committee of Medical Journal Editors (ICMJE) requirements should be verified. Trial sponsors should update registration status promptly as enrollment progresses.